Skip to main content

Table 3 EGFR exon 19del subtypes in patients

From: Investigating the genomic alteration improved the clinical outcome of aged patients with lung carcinoma

No.

Subtypes

Number of altered samples

TKI response (total = 26)a

PR, N

PD, N

1

c.2235_2249del

p.Glu746_Ala750del

20

10

2

2

c.2236_2250del

p.Glu746_Ala750del

13

7

1

3

c.2236_2248delinsAGCC

p.Glu746_Ala750delinsSerPro

1

 

1

4

c.2236_2252delinsCT

p.Glu746_Thr751delinsLeu

1

  

5

c.2236_2257delinsCTCT

p.Glu746_Pro753delinsLeuSer

1

  

6

c.2237_2252delinsT

p.Glu746_Thr751delinsVal

1

  

7

c.2237_2255delinsT

p.Glu746_Ser752delinsVal

1

1

 

8

c.2239_2247del

p.Leu747_Glu749del

1

  

9

c.2239_2256del

p.Leu747_Ser752del

1

  

10

c.2240_2254del

p.Leu747_Thr751del

2

1

1

11

c.2240_2257del

p.Leu747_Pro753delinsSer

5

2

 
  1. apatients received the first-generation TKI treatment
Back to article page

BMC Genomics

ISSN: 1471-2164

Contact us